ATE258597T1 - Cathepsin-g-hemmende aptamere - Google Patents

Cathepsin-g-hemmende aptamere

Info

Publication number
ATE258597T1
ATE258597T1 AT96118661T AT96118661T ATE258597T1 AT E258597 T1 ATE258597 T1 AT E258597T1 AT 96118661 T AT96118661 T AT 96118661T AT 96118661 T AT96118661 T AT 96118661T AT E258597 T1 ATE258597 T1 AT E258597T1
Authority
AT
Austria
Prior art keywords
cathepsin
inhibiting aptamers
aptamers
inhibiting
nucleotides
Prior art date
Application number
AT96118661T
Other languages
English (en)
Inventor
Franzpeter Bracht
Karsten Schroer
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Application granted granted Critical
Publication of ATE258597T1 publication Critical patent/ATE258597T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
AT96118661T 1995-11-24 1996-11-21 Cathepsin-g-hemmende aptamere ATE258597T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543750A DE19543750C2 (de) 1995-11-24 1995-11-24 Cathepsin G inhibierende Aptamere

Publications (1)

Publication Number Publication Date
ATE258597T1 true ATE258597T1 (de) 2004-02-15

Family

ID=7778263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96118661T ATE258597T1 (de) 1995-11-24 1996-11-21 Cathepsin-g-hemmende aptamere

Country Status (8)

Country Link
US (1) US5780449A (de)
EP (1) EP0775745B1 (de)
JP (1) JP4257939B2 (de)
AT (1) ATE258597T1 (de)
DE (2) DE19543750C2 (de)
DK (1) DK0775745T3 (de)
ES (1) ES2217297T3 (de)
PT (1) PT775745E (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682886B1 (en) * 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
WO1999050462A1 (en) * 1998-03-27 1999-10-07 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
DE19916417A1 (de) * 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
WO2002026932A2 (en) 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
PT2070939E (pt) * 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
DE60325564D1 (de) * 2002-03-05 2009-02-12 Univ Texas Biospezifische kontrastmittel
AU2003245676A1 (en) 2002-06-24 2004-01-06 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US20070003975A1 (en) * 2003-05-02 2007-01-04 Canon Kabushiki Kaisha Structured construct and producing method therefor
EP1493810A1 (de) * 2003-06-30 2005-01-05 Gentium S.p.A. Auf DNA-basierte Aptamere für Cathepsin G
JP4533044B2 (ja) * 2003-08-27 2010-08-25 キヤノン株式会社 センサ
CN1980947B (zh) * 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
EP1774575A2 (de) * 2004-05-17 2007-04-18 Cambrios Technology Corp. Biofabrikation von transistoren mit feldeffekttransistoren
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20100018674A1 (en) * 2008-07-22 2010-01-28 Donald John Enzinna Reservoir with moveable partition for quick recovery
CN111712573B (zh) * 2018-02-12 2023-10-20 安沛治疗有限公司 针对骨硬化蛋白的适体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
IE920562A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
AU655301B2 (en) * 1991-05-23 1994-12-15 Merrell Pharmaceuticals Inc. Inhibitors of cathepsin G and elastase for preventing connective tissue degradation
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides

Also Published As

Publication number Publication date
DE19543750A1 (de) 1997-07-03
DE69631409T2 (de) 2004-12-02
JP4257939B2 (ja) 2009-04-30
PT775745E (pt) 2004-06-30
EP0775745A3 (de) 1999-10-13
JPH09216895A (ja) 1997-08-19
US5780449A (en) 1998-07-14
DE69631409D1 (de) 2004-03-04
DE19543750C2 (de) 1997-10-23
DK0775745T3 (da) 2004-06-01
EP0775745B1 (de) 2004-01-28
ES2217297T3 (es) 2004-11-01
EP0775745A2 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
DE69631409D1 (de) Cathepsin-G-hemmende Aptamere
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
DK0785252T3 (da) Antisense-oligonukleotider mod den alfa-regulatoriske subunit af den cAMP-afhængige proteinkinase til behandling af cancer
DE69934010D1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
CY1105399T1 (el) Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων
EP1417351A4 (de) Antisense-modulation der expression von apolipoprotein(a)
DE50214266D1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
RU97120584A (ru) Ингибитор активности il-6
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
DE59607853D1 (de) G-Cap stabilisierte Oligonucleotide
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE60042585D1 (de) 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
EP1131107A4 (de) Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha
EP1131332A4 (de) Antisense-modulation der inhibitor-kappa b kinase-beta expression
ATE160354T1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
EP1165145A4 (de) Antisense-modulation der mdmx-expression
EP1248795A4 (de) Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors
ATE499941T1 (de) Kosmetisches oder therapeutisches kombinationsprcparat
EP1173458A4 (de) Antinsens modulierung der sra expression
ITTO940379A1 (it) Sequenze specifiche per il dna umano.
WO2002072883A3 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
FR2733913B1 (fr) Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
BR0016347A (pt) Oligonucleotìdios antisenso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0775745

Country of ref document: EP